## Yoon Yeo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2157865/publications.pdf

Version: 2024-02-01

117	8,905	49	92
papers	citations	h-index	g-index
119	119	119	13572
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Archives of Pharmacal Research, 2004, 27, 1-12.	2.7	460
2	Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery. Molecular Pharmaceutics, 2009, 6, 1041-1051.	2.3	405
3	Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2012, 4, 219-233.	3.3	393
4	Polydopamine-Based Simple and Versatile Surface Modification of Polymeric Nano Drug Carriers. ACS Nano, 2014, 8, 3347-3356.	7.3	363
5	Controlled drug release from pharmaceutical nanocarriers. Chemical Engineering Science, 2015, 125, 75-84.	1.9	359
6	Micromolding of photocrosslinkable chitosan hydrogel for spheroid microarray and co-cultures. Biomaterials, 2006, 27, 5259-5267.	5.7	309
7	Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies. Molecular Pharmaceutics, 2013, 10, 2093-2110.	2.3	274
8	The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives. Biomaterials, 2007, 28, 975-983.	5.7	239
9	Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials, 2009, 30, 1947-1953.	5.7	235
10	Hyaluronic Acid-Based Microgels and Microgel Networks for Vocal Fold Regeneration. Biomacromolecules, 2006, 7, 3336-3344.	2.6	221
11	Intracellular Drug Delivery by Poly(lactic- <i>co</i> -glycolic acid) Nanoparticles, Revisited. Molecular Pharmaceutics, 2009, 6, 190-201.	2.3	210
12	In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model. Biomaterials, 2006, 27, 4698-4705.	5.7	205
13	Complex Coacervates for Thermally Sensitive Controlled Release of Flavor Compounds. Journal of Agricultural and Food Chemistry, 2005, 53, 7518-7525.	2.4	184
14	Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. Journal of Biomedical Materials Research - Part A, 2006, 77A, 351-361.	2.1	182
15	Release Kinetics Study of Poorly Water-Soluble Drugs from Nanoparticles: Are We Doing It Right?. Molecular Pharmaceutics, 2015, 12, 997-1003.	2.3	178
16	Intratumoral Drug Delivery with Nanoparticulate Carriers. Pharmaceutical Research, 2011, 28, 1819-1830.	1.7	145
17	Microencapsulation methods for delivery of protein drugs. Biotechnology and Bioprocess Engineering, 2001, 6, 213-230.	1.4	140
18	Low Molecular-Weight Chitosan as a pH-Sensitive Stealth Coating for Tumor-Specific Drug Delivery. Molecular Pharmaceutics, 2012, 9, 1262-1270.	2.3	131

#	Article	IF	CITATIONS
19	Dextran-based in situ cross-linked injectable hydrogels to prevent peritoneal adhesions. Biomaterials, 2007, 28, 3418-3426.	5.7	126
20	Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. Journal of Controlled Release, 2012, 158, 386-392.	4.8	123
21	Quantitative Assessment of Nanoparticle Biodistribution by Fluorescence Imaging, Revisited. ACS Nano, 2018, 12, 6458-6468.	7.3	123
22	A photolithographic method to create cellular micropatterns. Biomaterials, 2006, 27, 4755-4764.	5.7	118
23	Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone. Biomaterials, 2007, 28, 1778-1786.	5.7	115
24	Photocrosslinkable hydrogel for myocyte cell culture and injection. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2007, 81B, 312-322.	1.6	113
25	Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. Biomaterials, 2018, 180, 206-224.	5.7	110
26	Polymers in the prevention of peritoneal adhesions. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 57-66.	2.0	108
27	Tannic Acid-Mediated Surface Functionalization of Polymeric Nanoparticles. ACS Biomaterials Science and Engineering, 2016, 2, 2294-2303.	2.6	104
28	Antifungal hydrogels. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12994-12998.	3.3	101
29	Nanocrystals for the parenteral delivery of poorly water-soluble drugs. Current Opinion in Solid State and Materials Science, 2012, 16, 295-301.	5.6	100
30	Zwitterionic Chitosan Derivatives for pH-Sensitive Stealth Coating. Biomacromolecules, 2010, 11, 2352-2358.	2.6	97
31	Drug delivery to macrophages: Challenges and opportunities. Journal of Controlled Release, 2016, 240, 202-211.	4.8	96
32	In Situ Cross-linkable Hyaluronan Hydrogels Containing Polymeric Nanoparticles for Preventing Postsurgical Adhesions. Annals of Surgery, 2007, 245, 819-824.	2.1	95
33	Drug Delivery Systems for Intraperitoneal Therapy. Pharmaceutical Research, 2010, 27, 735-738.	1.7	94
34	Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine. Biomaterials, 2009, 30, 5834-5843.	5.7	86
35	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine–Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. ACS Nano, 2017, 11, 10135-10146.	7.3	84
36	Polymer–iron oxide composite nanoparticles for EPR-independent drug delivery. Biomaterials, 2016, 101, 285-295.	5.7	78

#	Article	IF	Citations
37	Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Advanced Drug Delivery Reviews, 2016, 104, 93-109.	6.6	77
38	Rapidly Photo-Cross-Linkable Chitosan Hydrogel for Peripheral Neurosurgeries. Biomacromolecules, 2011, 12, 57-65.	2.6	76
39	Albumin-coated nanocrystals for carrier-free delivery of paclitaxel. Journal of Controlled Release, 2017, 263, 90-101.	4.8	<b>7</b> 5
40	Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials, 2015, 37, 312-319.	5.7	74
41	A new process for making reservoir-type microcapsules using ink-jet technology and interfacial phase separation. Journal of Controlled Release, 2003, 93, 161-173.	4.8	69
42	Application of polysaccharides for surface modification of nanomedicines. Therapeutic Delivery, 2012, 3, 1447-1456.	1.2	66
43	Polydopamine-Based Surface Modification for the Development of Peritumorally Activatable Nanoparticles. Pharmaceutical Research, 2013, 30, 1956-1967.	1.7	66
44	A new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchange. Journal of Controlled Release, 2004, 100, 379-388.	4.8	65
45	Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide. Journal of Controlled Release, 2007, 120, 178-185.	4.8	62
46	Peritoneal application of chitosan and UVâ€crossâ€linkable chitosan. Journal of Biomedical Materials Research - Part A, 2006, 78A, 668-675.	2.1	60
47	Mannitolâ€Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnology and Bioengineering, 2011, 108, 1441-1449.	1.7	59
48	Particle engineering for intracellular delivery of vancomycin to methicillin-resistant Staphylococcus aureus (MRSA)-infected macrophages. Journal of Controlled Release, 2017, 267, 133-143.	4.8	56
49	Low molecular weight chitosan-coated polymeric nanoparticles for sustained and pH-sensitive delivery of paclitaxel. Journal of Drug Targeting, 2015, 23, 725-735.	2.1	51
50	Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity. Nano Letters, 2019, 19, 8333-8341.	4.5	51
51	Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages. Pharmaceutical Research, 2019, 36, 65.	1.7	50
52	Bioresorbable, Miniaturized Porous Silicon Needles on a Flexible Water-Soluble Backing for Unobtrusive, Sustained Delivery of Chemotherapy. ACS Nano, 2020, 14, 7227-7236.	7.3	50
53	Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis. Pharmaceutical Research, 2010, 27, 151-160.	1.7	49
54	Zwitterionic Chitosan Derivative, a New Biocompatible Pharmaceutical Excipient, Prevents Endotoxin-Mediated Cytokine Release. PLoS ONE, 2012, 7, e30899.	1.1	48

#	Article	IF	CITATIONS
55	Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model. Biomaterials, 2007, 28, 3704-3713.	5.7	47
56	A Comparative In Vivo Study of Albuminâ€Coated Paclitaxel Nanocrystals and Abraxane. Small, 2018, 14, e1703670.	5.2	47
57	Zwitterionic Chitosan–Polyamidoamine Dendrimer Complex Nanoparticles as a pH-Sensitive Drug Carrier. Molecular Pharmaceutics, 2013, 10, 1695-1704.	2.3	44
58	Development of Liposomal Gemcitabine with High Drug Loading Capacity. Molecular Pharmaceutics, 2019, 16, 2858-2871.	2.3	44
59	Solvent Exchange Method: A Novel Microencapsulation Technique Using Dual Microdispensers. Pharmaceutical Research, 2004, 21, 1419-1427.	1.7	42
60	Cancer targeting strategies in nanomedicine: Design and application of chitosan nanoparticles. Current Opinion in Solid State and Materials Science, 2012, 16, 333-342.	5.6	42
61	Semi-interpenetrating network of polyethylene glycol and photocrosslinkable chitosan as an in-situ-forming nerve adhesive. Acta Biomaterialia, 2012, 8, 1849-1858.	4.1	42
62	Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals. Journal of Controlled Release, 2016, 235, 91-98.	4.8	42
63	Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. Journal of Controlled Release, 2019, 302, 148-159.	4.8	41
64	Photocrosslinkable chitosan modified with angiopoietinâ€1 peptide, QHREDGS, promotes survival of neonatal rat heart cells. Journal of Biomedical Materials Research - Part A, 2010, 95A, 105-117.	2.1	40
65	Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, Enables Systemic Delivery of siRNA to Solid Tumors. ACS Nano, 2021, 15, 4576-4593.	7.3	39
66	In-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate. Biomaterials, 2019, 217, 119296.	5.7	37
67	Beyond the imaging: Limitations of cellular uptake study in the evaluation of nanoparticles. Journal of Controlled Release, 2012, 164, 170-176.	4.8	35
68	Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opinion on Drug Delivery, 2014, 11, 1601-1618.	2.4	33
69	Antibacterial nanotruffles for treatment of intracellular bacterial infection. Biomaterials, 2020, 262, 120344.	<b>5.7</b>	33
70	Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics. AAPS Journal, 2008, 10, 254-60.	2.2	31
71	A strategy to deliver genes to cystic fibrosis lungs: A battle with environment. Journal of Controlled Release, 2011, 155, 289-295.	4.8	30
72	Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities. Journal of Controlled Release, 2021, 330, 438-460.	4.8	28

#	Article	IF	Citations
73	Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opinion on Drug Delivery, 2011, 8, 451-466.	2.4	26
74	Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals. Molecular Pharmaceutics, 2018, 15, 871-881.	2.3	25
75	Quinic Acidâ€Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. Small, 2018, 14, e1803601.	5.2	25
76	Small molecule delivery to solid tumors with chitosan-coated PLGA particles: A lesson learned from comparative imaging. Journal of Controlled Release, 2017, 268, 407-415.	4.8	24
77	Camouflaging Nanoparticles for Ratiometric Delivery of Therapeutic Combinations. Nano Letters, 2019, 19, 1479-1487.	4.5	24
78	Reservoir-Type Microcapsules Prepared by the Solvent Exchange Method:  Effect of Formulation Parameters on Microencapsulation of Lysozyme. Molecular Pharmaceutics, 2006, 3, 135-143.	2.3	23
79	Effects of So-cheong-ryong-tang and Yeon-gyo-pae-dok-san on the common cold: Randomized, double blind, placebo controlled trial. Journal of Ethnopharmacology, 2011, 133, 642-646.	2.0	23
80	Development of Quinic Acid-Conjugated Nanoparticles as a Drug Carrier to Solid Tumors. Biomacromolecules, 2013, 14, 2389-2395.	2.6	23
81	Recent advances in nanomedicine for sepsis treatment. Therapeutic Delivery, 2018, 9, 435-450.	1.2	23
82	Development of inhalable dry powder formulation of basic fibroblast growth factor. International Journal of Pharmaceutics, 2010, 385, 66-72.	2.6	21
83	Extracellular stability of nanoparticulate drug carriers. Archives of Pharmacal Research, 2014, 37, 16-23.	2.7	21
84	Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy. Expert Opinion on Drug Delivery, 2017, 14, 427-446.	2.4	21
85	Succinylated Chitosan Derivative Has Local Protective Effects on Intestinal Inflammation. ACS Biomaterials Science and Engineering, 2017, 3, 1853-1860.	2.6	21
86	Development of Surface-Variable Polymeric Nanoparticles for Drug Delivery to Tumors. Molecular Pharmaceutics, 2017, 14, 1538-1547.	2.3	20
87	Nanocapsules modify membrane interaction of polymyxin B to enable safe systemic therapy of Gram-negative sepsis. Science Advances, 2021, $7$ , .	4.7	20
88	Prevention of peritoneal adhesions using polymeric rheological blends. Acta Biomaterialia, 2014, 10, 1187-1193.	4.1	19
89	Reliability and validity of Leicester Cough Questionnaire Korean version. Chronic Respiratory Disease, 2014, 11, 147-152.	1.0	18
90	Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD. Journal of Ethnopharmacology, 2014, 151, 123-130.	2.0	18

#	Article	IF	CITATIONS
91	Topical application of zwitterionic chitosan suppresses neutrophil-mediated acute skin inflammation. International Journal of Biological Macromolecules, 2020, 158, 1184-1193.	3.6	14
92	Radiation-enhanced delivery of plasmid DNA to tumors utilizing a novel PEI polyplex. Cancer Gene Therapy, 2018, 25, 196-206.	2.2	13
93	Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine. AAPS PharmSciTech, 2018, 19, 693-699.	1.5	13
94	Microenvironment-Controlled Encapsulation (MiCE) Process: Effects of PLGA Concentration, Flow Rate, and Collection Method on Microcapsule Size and Morphology. Pharmaceutical Research, 2008, 25, 5-15.	1.7	12
95	A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge. Veterinary Immunology and Immunopathology, 2013, 152, 359-369.	0.5	12
96	Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy. Journal of Controlled Release, 2022, 345, 586-600.	4.8	12
97	Differential Effects of Insufflated, Subcutaneous, and Intravenous Growth Hormone on Bone Growth, Cognitive Function, and NMDA Receptor Subunit Expression. Endocrinology, 2010, 151, 4418-4427.	1.4	11
98	Zwitterionic chitosan for the systemic treatment of sepsis. Scientific Reports, 2016, 6, 29739.	1.6	11
99	Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam. Journal of Controlled Release, 2022, 342, 189-200.	4.8	11
100	Drug Carriers: Not an Innocent Delivery Man. AAPS Journal, 2015, 17, 1096-1104.	2.2	10
101	A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
102	Magnetophoretic Delivery of a Tumor-Priming Agent for Chemotherapy of Metastatic Murine Breast Cancer. Molecular Pharmaceutics, 2019, 16, 1864-1873.	2.3	9
103	Engineering microenvironment of biodegradable polyester systems for drug stability and release control. Therapeutic Delivery, 2021, 12, 37-54.	1.2	9
104	Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer. Pharmaceuticals, 2021, 14, 925.	1.7	7
105	Stabilization of a hyaluronate-associated gene delivery system using calcium ions. Biomaterials Science, 2014, 2, 936-942.	2.6	6
106	Polyethylenimine-Dermatan Sulfate Complex, a Bioactive Biomaterial with Unique Toxicity to CD146-Positive Cancer Cells. ACS Biomaterials Science and Engineering, 2017, 3, 990-999.	2.6	6
107	Effects of Inhalable Microparticles of on Chronic Obstructive Pulmonary Disease in a Mouse Model. Journal of Korean Medicine, 2013, 34, 54-68.	0.1	6
108	Effects of Inhalable Microparticles of Seonpyejeongcheon-Tang in an Asthma Mouse Model - Effects of Microparticles of SJT Journal of Pharmacopuncture, 2016, 19, 303-311.	0.4	5

## YOON YEO

#	Article	IF	Citations
109	Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections. Pharmaceutical Research, 2022, 39, 1085-1114.	1.7	5
110	Battling with environments: drug delivery to target tissues with particles and functional biomaterials. Therapeutic Delivery, 2010, 1, 757-761.	1.2	4
111	Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. Journal of Pharmaceutical Sciences, 2020, 109, 1615-1622.	1.6	3
112	Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. Journal of Pharmaceutical Investigation, 2021, 51, 483.	2.7	3
113	A New Microencapsulation Technique Based on the Solvent Exchange Method. ACS Symposium Series, 2006, , 242-252.	0.5	2
114	Nanoparticles for tumor-specific intracellular drug delivery. , 2009, 2009, 2403-5.		2
115	Photo-crosslinkable chitosan hydrogel as a bioadhesive for esophageal stents. Macromolecular Research, 2015, 23, 882-884.	1.0	2
116	A Photo-Crosslinkable Chitosan Hydrogel for Peripheral Nerve Anastomosis. , 2009, , .		1
117	Local immunotherapy of cancer and metastasis. , 2022, , 483-528.		1